이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Melodiol Global Health 관리

관리 기준 확인 1/4

Melodiol Global Health's CEO는 Will Lay, Jan2022 에 임명되었습니다 의 임기는 2.42 년입니다. 총 연간 보상은 A$ 894.88K, 46% 로 구성됩니다. 46% 급여 및 54% 보너스(회사 주식 및 옵션 포함). 는 A$ 2.35K 가치에 해당하는 회사 주식의 0.38% 직접 소유합니다. 2.35K. 경영진과 이사회의 평균 재임 기간은 각각 4 년과 2.4 년입니다.

주요 정보

Will Lay

최고 경영자

AU$894.9k

총 보상

CEO 급여 비율	46.0%
CEO 임기	2.8yrs
CEO 소유권	0.006%
경영진 평균 재임 기간	4.3yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Will Lay 의 보수는 Melodiol Global Health 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	AU$895k	AU$412k	-AU$36m
Jun 30 2023	n/a	n/a	-AU$54m
Mar 31 2023	n/a	n/a	-AU$43m
Dec 31 2022	AU$408k	AU$389k	-AU$22m

보상 대 시장: Will 의 총 보상 ($USD 596.98K )은 Australian 시장( $USD 298.77K ).

보상과 수익: 회사가 수익성이 없는 동안 Will 의 보상이 증가했습니다.

CEO

Will Lay

2.8yrs

테뉴어

AU$894,875

보상

Mr. William Lay, also known as Will, B.Com (Hons.) is CEO & MD of Health House International Limited from 2024. He serves as Group Chief Executive Officer, Managing Director and Director at Melodiol Global...

리더십 팀

이름	위치	테뉴어	보상	소유권
Boaz Wachtel	Co-Founder & Non-Executive Chairman	8.9yrs	AU$80.00k	0.0015% A$ 17.2
William Lay	Group CEO	2.8yrs	AU$894.88k	0.0063% A$ 70.8
Christopher Grundy	Chief Financial Officer	6.9yrs	AU$628.01k	0.00014% A$ 1.6
Micheline MacKay	Executive Director	2.8yrs	AU$265.90k	0.00046% A$ 5.2
Gian Trepp	Commercial & Marketing Director	5.8yrs	데이터 없음	데이터 없음
Mitchel Fleming	Managing Director of Halucenex	no data	데이터 없음	데이터 없음
Brett Ayers	Managing Director of Impactive	no data	데이터 없음	데이터 없음
Winton Willesee	Joint Company Secretary	6yrs	데이터 없음	데이터 없음
Brian Walker	Strategic Consultant & Chair of Scientific Advisory Committee	2.9yrs	데이터 없음	데이터 없음

4.3yrs

평균 재임 기간

경험이 풍부한 관리: ME1 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Boaz Wachtel	Co-Founder & Non-Executive Chairman	8.9yrs	AU$80.00k	0.0015% A$ 17.2
William Lay	Group CEO	2.8yrs	AU$894.88k	0.0063% A$ 70.8
Micheline MacKay	Executive Director	2.8yrs	AU$265.90k	0.00046% A$ 5.2
Brian Walker	Strategic Consultant & Chair of Scientific Advisory Committee	2.9yrs	데이터 없음	데이터 없음
Walter Von Wartburg	Member of Scientific Advisory Board	5.8yrs	데이터 없음	데이터 없음
Bruce Linton	Independent Non-Executive Director	2.8yrs	AU$82.72k	0.0019% A$ 22.0
Isaac Kobrin	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Felix Gutzwiller	Member of Scientific Advisory Board	7.6yrs	데이터 없음	데이터 없음
Peter Hatfull	Non-Executive Director	1.9yrs	AU$83.26k	데이터 없음
Ben Quirin	Non-Executive Director	2yrs	AU$82.80k	데이터 없음

2.8yrs

평균 재임 기간

73.5yo

평균 연령

경험이 풍부한 이사회: ME1 의 이사회는 경험(평균 재직 기간 2.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Melodiol Global Health 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Less than half of directors are independent

Creso Pharma Limited Announces Board Changes

Less than half of directors are independent

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

Recent updates

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

New major risk - Negative shareholders equity

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.45 loss in FY 2022)

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited Option Expiring 13 November 2028 Deferred Settlement Deleted from OTC Equity

Less than half of directors are independent

Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.027 loss in FY 2021)

Creso Pharma Limited (ASX:CPH) entered into a binding letter of intent to acquire Abby & Finn, LLC for $2.5 million.

Creso Pharma Limited Announces Board Changes

Less than half of directors are independent

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

First half 2022 earnings released: AU$0.006 loss per share (vs AU$0.018 loss in 1H 2021)

Sierra Sage Secures USD 214,000 Purchase Order from Walmart

Creso Pharma Limited (ASX:CPH) signed a non-binding, non-exclusive heads of agreement to acquire Dr Pickles Pty Ltd.

Less than half of directors are independent

Creso Pharma Limited, Annual General Meeting, May 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Creso Pharma Limited announced that it expects to receive AUD 5 million in funding

Creso Pharma to Develop New Hemp-Based Lozenge Product

Creso Pharma Limited Launches New E-Commerce Channels

Creso Pharma Limited (ASX:CPH) completed the acquisition of Halucenex Life Sciences Inc.

Co-Founder & Non-Executive Chairman recently sold AU$4.5m worth of stock

Creso Pharma Limited Launches New Product

Creso Pharma Limited (ASX:CPH) entered into an agreement to acquire Halucenex Life Sciences Inc. CAD 10 million.

Creso Pharma Limited Signs Non-Binding Letter of Intent with ImpACTIVE Holdings Ltd

Full year 2020 earnings released: AU$0.083 loss per share (vs AU$0.10 loss in FY 2019)

Creso Pharma Limited Executes A Non-Binding Letter of Intent with Ceres Natural Remedies

Creso Pharma Limited Revises Earnings Guidance for the Fiscal Year 2021

Creso Pharma Limited Announces Distribution Agreement with Route2 Pharm Pvt Ltd

CBD Oil legal in Australia - Creso Pharma Limited to benefit

Creso Pharma Limited has announced a Derivatives Offering in the amount of AUD 9.523042 million.

Creso Pharma Limited Secures New Purchase Order for its Leading Range of Animal Health Products Anibidiol

Creso Pharma Limited Secures First Purchase Order for Animal Health Products in LATAM

Creso Pharma Limited Announces TGA Decision to Reschedule CBD

New 90-day high: AU$0.24

Creso Pharma Limited Receives New Purchase Orders for Anibidiol® Products

Creso Pharma Limited Receives Second Purchase Order from Pharma Dynamics, South Africa

Creso Pharma Limited announced that it expects to receive AUD 8.992531 million in funding

First half earnings released

Creso Pharma Limited Announces CEO, Miri Halperin Wernli to Take Role of Technology, Innovation and Distribution Head

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령